Jerel A. Banks - 18 Nov 2025 Form 4 Insider Report for Benitec Biopharma Inc. (BNTC)

Reporting relationship
Chief Executive Officer, Director
Issuer ticker
BNTC
Reported as of
18 Nov 2025
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
20 Nov 2025, 17:36:30 UTC
Prior SEC filing
11 Dec 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Jerel A. Banks

Key filing fact

Jerel A. Banks filed Form 4 for Benitec Biopharma Inc. (BNTC) on 20 Nov 2025.

Key facts

  • This page summarizes Jerel A. Banks's Form 4 filing for Benitec Biopharma Inc. (BNTC).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 20 Nov 2025, 17:36.

Change

  • Previous filing in this sequence was filed on 11 Dec 2024.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001808930 Primary reporting owner

Banks Jerel A.

Relationship
Chief Executive Officer, Director
Address
C/O BENITEC BIOPHARMA INC., 3940 TRUST WAY, HAYWARD
Signature
/s/ Jerel A. Banks
Signature date
20 Nov 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BNTC transaction Derivative

Options (right to buy)

Award

Transaction value
$0
Shares
+450,000
Change %
Price
$0.000000
Shares after
450,000
Date
18 Nov 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
450,000
Exercise price
$13.53
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The stock options will vest in 16 substantially equal quarterly installments commencing on March 31, 2026.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .